BTIG Reaffirms Their Buy Rating on Haemonetics (HAE)
BTIG analyst Marie Thibault maintained a Buy rating on Haemonetics today and set a price target of $84.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Thibault covers the Healthcare sector, focusing on stocks such as Boston Scientific, Kestra Medical Technologies Ltd., and Dexcom. According to TipRanks, Thibault has an average return of -14.5% and a 31.59% success rate on recommended stocks.
Haemonetics has an analyst consensus of Moderate Buy, with a price target consensus of $82.17.
Based on Haemonetics’ latest earnings release for the quarter ending December 27, the company reported a quarterly revenue of $338.97 million and a net profit of $44.74 million. In comparison, last year the company earned a revenue of $348.54 million and had a net profit of $37.49 million
Read More on HAE:
Disclaimer & DisclosureReport an Issue
- Haemonetics price target lowered to $64 from $70 at Citi
- Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27
- Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system
- Haemonetics price target lowered to $70 from $75 at Citi
- Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure
